Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Trans-Resveratrol-Loaded Nanostructured Lipid Carrier Formulations for Pulmonary Drug Delivery Using Medical Nebulizers

Khan, I, Sabu, M, Hussein, N, Omer, H, Houacine, C, Khan, W, Elhissi, A and Yousaf, S (2025) Trans-Resveratrol-Loaded Nanostructured Lipid Carrier Formulations for Pulmonary Drug Delivery Using Medical Nebulizers. Journal of Pharmaceutical Sciences. ISSN 0022-3549

[img]
Preview
Text
Trans-Resveratrol-Loaded Nanostructured Lipid Carrier Formulations for Pulmonary Drug Delivery Using Medical Nebulizers.pdf - Accepted Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Aerosolization is a non-invasive approach of delivering drugs for both localized and systemic effects, specifically pulmonary targeting. The aim of this study was to deliver trans-resveratrol (TR) as an anti-cancer drug entrapped in a new generation versatile carriers nanostructured lipid carrier (NLC) to protect degradation and improve bioavailability via medical nebulizers. Twelve TR-NLC (i.e., F1-F12) formulations were prepared using different combinations and ratios of formulation ingredients via hot high-pressure homogenization. Upon analysis, formulations F1 and F2 demonstrated a particle size of <185 nm, a polydispersity index (PDI) <0.25, Zeta potential values of ∼30 mV and an entrapment efficiency >94%. The aerosolization performance of the F1 and F2 formulations was performed via a next generation impactor (NGI), using medical nebulizers. The air jet nebulizer demonstrated lower drug deposition in the earlier stages (1-2) and significantly higher deposition in the latter stages 3-5 (for both formulations), targeting middle to lower lung deposition. Moreover, the air jet nebulizer exhibited significantly higher emitted dose (ED) (87.44 ± 3.36%), fine particle dose (FPD) (1652.52 ± 9.68 µg) fine particle fraction (FPF) (36.25 ± 4.26%), and respirable fraction (RF) (93.41 ± 4.03%) when the F1 formulation was used as compared to the F2 formulation. Thus, the TR-NLC F1 formulation and air jet nebulizer were identified as the best combination for the delivery and targeting peripheral lungs.

Item Type: Article
Additional Information: Replace with VOR KJ 10/3/25
Uncontrolled Keywords: Cancer; Drug delivery; Liquid lipid; Medical nebulizer; Pulmonary system; Solid lipid; 3206 Medical Biotechnology; 32 Biomedical and Clinical Sciences; Biotechnology; Cancer; Lung; 5.1 Pharmaceuticals; 1115 Pharmacology and Pharmaceutical Sciences; Pharmacology & Pharmacy; 3214 Pharmacology and pharmaceutical sciences
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
T Technology > TA Engineering (General). Civil engineering (General)
Divisions: Engineering
Pharmacy and Biomolecular Sciences
Publisher: Elsevier
SWORD Depositor: A Symplectic
Date Deposited: 10 Mar 2025 13:57
Last Modified: 10 Mar 2025 14:00
DOI or ID number: 10.1016/j.xphs.2025.103713
URI: https://researchonline.ljmu.ac.uk/id/eprint/25838
View Item View Item